Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review

Résumé fourni par la source

OBJECTIVE: To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. METHODS: Relevant published evidence from real-world studies and clinical trials that met defined criteria was identified through targeted searches of PubMed, supplemented by manual reviews of reference lists and input from authors. RESULTS: In real-world studies of patients with treatment failure on anti-IL-17 agents (secukinumab and/or ixekizumab), brodalumab achieved PASI 75, PASI 90, and PASI 100 in 47.8%-81.7%, 40.0%-58.9%, and 28.0%-50.0% of patients, respectively, after 12-16 weeks of treatment. PASI 100 was achieved by 45.5%-63.6% of patients with 26 weeks of brodalumab therapy after anti-IL-12/23, anti-IL-23, or anti-tumor necrosis factor alpha agents in a phase 4 study. Studies with longer-term follow-up have suggested that responses to brodalumab are durable in biologic-experienced patients. CONCLUSIONS: Literature evaluated in this narrative review positions brodalumab as a rational, safe, and effective treatment option for adults with moderate to severe plaque psoriasis who have an inadequate response/loss of an initial response to their existing biologic agent.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.